Giancarlo Maria Liumbruno
Overview
Explore the profile of Giancarlo Maria Liumbruno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
932
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Franchini M, Baldanti F, Percivalle E, Ferrari A, Biasi P, Liumbruno G, et al.
Transfus Clin Biol
. 2021 Aug;
29(1):101-102.
PMID: 34391625
No abstract available.
2.
Franchini M, Glingani C, Liumbruno G, Mengoli C
Transfus Apher Sci
. 2021 Jul;
60(6):103216.
PMID: 34315677
No abstract available.
3.
Pezzo M, Orioli M, Pagani M, Caiola S, Liumbruno G, Franchini M
Diagnosis (Berl)
. 2021 Jul;
12(1):141-143.
PMID: 34214292
No abstract available.
4.
Franchini M, Liumbruno G, Pezzo M
Eur J Haematol
. 2021 May;
107(2):173-180.
PMID: 33987882
Very rare cases of thrombosis associated with thrombocytopenia have occurred following the vaccination with AstraZeneca COVID-19 vaccine. The aim of this concise review is to summarize the current knowledge on...
5.
Franchini M, Liumbruno G, Piacentini G, Glingani C, Zaffanello M
Life (Basel)
. 2021 Apr;
11(4).
PMID: 33919577
The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread rapidly around the world in the last year causing the coronavirus disease 2019 (COVID-19), which still is a...
6.
Franchini M, Schiavulli M, Liumbruno G
Expert Rev Hematol
. 2021 Mar;
14(3):263-270.
PMID: 33655810
: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.: The main epidemiological, clinical,...
7.
Franchini M, Glingani C, Liumbruno G
Diagnosis (Berl)
. 2021 Mar;
8(4):413-420.
PMID: 33652503
The COVID-19 pandemic will be remembered as one of the worst catastrophic events in human history. Unfortunately, no universally recognized effective therapeutic agents are currently available for the treatment of...
8.
Franchini M, Liumbruno G
Biologics
. 2021 Feb;
15:31-38.
PMID: 33574654
The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent...
9.
Del Fante C, Franchini M, Baldanti F, Percivalle E, Glingani C, Marano G, et al.
Transfusion
. 2020 Nov;
61(3):830-838.
PMID: 33231325
Background: Although many trials are currently investigating the safety and efficacy of convalescent plasma (CP) in critically ill COVID-19 patients, there is a paucity of ongoing and published studies evaluating...
10.
Cruciani M, Franchini M, Mengoli C, Marano G, Pati I, Masiello F, et al.
Intern Emerg Med
. 2020 Sep;
16(1):209-220.
PMID: 32930966
Hemostatic resuscitation is currently considered a standard of care for the management of life-threatening hemorrhage, but in some critical settings the access to high quantities of blood components is problematic....